Dermorphin

What is Dermorphin?

Dermorphin stands as one of pharmacology's most intriguing discoveries. Isolated from the skin secretions of South American Phyllomedusa frogs, this heptapeptide contains an unusual D-alanine in position 2—one of the rare instances of D-amino acids in biologically active peptides. This structural quirk contributes to dermorphin's exceptional properties: nanomolar μ-opioid receptor affinity, selectivity ratios exceeding 1000:1 for μ over δ and κ receptors, and resistance to peptidase degradation.

The peptide's extraordinary selectivity and potency have made it an essential tool in opioid receptor biology—enabling precise study of μ-opioid receptor pharmacology, structure-activity relationships, and receptor-ligand interactions. Researchers investigating opioid signaling mechanisms, studying receptor binding kinetics, or exploring the structural determinants of receptor selectivity consistently rely on dermorphin as a reference μ-selective agonist.

Mechanism of Action

Dermorphin operates as an extraordinarily selective μ-opioid receptor (MOR) agonist with 1000-fold preference for μ versus δ or κ receptors. The D-Ala substitution at position 2—highly unusual in naturally occurring peptides—creates a structural conformation that optimizes MOR binding while preventing δ-opioid receptor (DOR) and κ-opioid receptor (KOR) interaction. Upon MOR binding, dermorphin activates Gαi/o proteins, inhibiting adenylyl cyclase (reducing cAMP), activating potassium channels (hyperpolarizing neurons), and inhibiting calcium channels (reducing neurotransmitter release). These combined effects suppress neuronal excitability and synaptic transmission.

The peptide demonstrates 30-100 fold greater analgesic potency than morphine in equimolar comparisons, attributed to its exceptional receptor affinity (KD ~0.3 nM) and intrinsic efficacy. The D-amino acid confers proteolytic resistance—dermorphin resists peptidase degradation that rapidly inactivates endogenous opioids like endorphins and enkephalins, extending its duration of action. Dermorphin's selectivity makes it invaluable for dissecting μ-receptor-specific signaling: effects observed with dermorphin can be definitively attributed to MOR activation without confounding δ or κ receptor activity.

Key Research Findings

• Demonstrates KD of 0.34 nM for μ-opioid receptors with >1000-fold selectivity over δ and κ receptors [Montecucchi et al., 1981]
• Produces analgesia 100-fold more potent than morphine (ED50 0.01 mg/kg vs 1.0 mg/kg) in tail-flick test [Broccardo et al., 1981]
• Shows 6-8 hour duration of antinociceptive action vs 2-3 hours for morphine due to D-Ala proteolytic stability [Erspamer et al., 1981]
• Completely reversed by naloxone (IC50 2.1 nM), confirming pure opioid receptor mechanism [Kreil et al., 1989]
• Induces μ-receptor internalization at 100-fold lower concentrations than endogenous β-endorphin [Sternini et al., 1996]

Research Applications

• μ-opioid receptor pharmacology
• Receptor subtype selectivity studies
• Opioid receptor binding kinetics
• Structure-activity relationships
• Receptor signaling mechanisms
• D-amino acid peptide biology
• Opioid tolerance mechanisms

Reconstitution & Use

Reconstitute with bacteriostatic water for laboratory use. For detailed reconstitution instructions and concentration ratios for your specific research application, see our reconstitution guide.

Storage & Handling

Store lyophilized at -20°C protected from moisture and light. Upon reconstitution with sterile or bacteriostatic water, maintain at 2-8°C and use within 30 days. The D-amino acid provides proteolytic resistance.